Dermata Therapeutics Stock Piotroski F Score
| DRMA Stock | USD 0.33 0.01 3.15% |
Dermata | Piotroski F Score |
At this time, it appears that Dermata Therapeutics' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Frail
| Current Return On Assets | Negative |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | No Change |
| Current Ratio Change | Decrease |
| Long Term Debt Over Assets Change | Lower Leverage |
| Change In Outstending Shares | Increase |
| Change in Gross Margin | No Change |
Dermata Therapeutics Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Dermata Therapeutics is to make sure Dermata is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Dermata Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Dermata Therapeutics' financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Current Liabilities | 1.5 M | 1.6 M |
|
| |||||
| Non Current Liabilities Total | 795.5 M | 757.6 M |
|
| |||||
| Total Assets | 6.4 M | 8 M |
|
| |||||
| Total Current Assets | 6.4 M | 8 M |
|
|
Dermata Therapeutics F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Dermata Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Dermata Therapeutics in a much-optimized way.
| -0.84 | -0.89 | 0.44 | 0.75 | 0.75 | -0.55 | ||
| -0.84 | 0.57 | -0.54 | -0.98 | -0.98 | 0.76 | ||
| -0.89 | 0.57 | -0.13 | -0.44 | -0.44 | 0.44 | ||
| 0.44 | -0.54 | -0.13 | 0.47 | 0.47 | -0.5 | ||
| 0.75 | -0.98 | -0.44 | 0.47 | 1.0 | -0.75 | ||
| 0.75 | -0.98 | -0.44 | 0.47 | 1.0 | -0.75 | ||
| -0.55 | 0.76 | 0.44 | -0.5 | -0.75 | -0.75 |
Click cells to compare fundamentals
About Dermata Therapeutics Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
About Dermata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dermata Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Dermata Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dermata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Dermata Stock
| 0.73 | ELYM | Eliem Therapeutics | PairCorr |
| 0.53 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.53 | XFOR | X4 Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
| 0.49 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.47 | ELEV | Elevation Oncology Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Dermata Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dermata Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dermata Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dermata Therapeutics to buy it.
The correlation of Dermata Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dermata Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dermata Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dermata Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Dermata Therapeutics Altman Z Score, Dermata Therapeutics Correlation, Dermata Therapeutics Valuation, as well as analyze Dermata Therapeutics Alpha and Beta and Dermata Therapeutics Hype Analysis. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Dermata Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.67) | Return On Assets (0.67) | Return On Equity (1.26) |
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.